Arrowhead Pharmaceuticals (ARWR) vs TG Therapeutics (TGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Arrowhead Pharmaceuticals (ARWR) has outperformed TG Therapeutics (TGTX) over the past year, gaining 64.4% versus a gain of 49.2%. Over five years, TGTX leads with a +60.1% price change compared with -8.2% for ARWR. Arrowhead Pharmaceuticals is the larger company by market cap ($8.86 billion vs $8.48 billion), about 1.0 times the size.
TG Therapeutics converts more of its revenue into profit, with a net margin of 72.6% versus -0.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARWR | TGTX |
|---|---|---|
| Share price | $62.75 | $55.37 |
| Market cap | $8.86B | $8.48B |
| 1-day change | +3.31% | +3.81% |
| YTD return | -8.51% | +78.93% |
| 1-year return | +64.43% | +49.20% |
| 5-year return | -8.19% | +60.13% |
| P/E ratio (TTM) | — | 19.43 |
| Forward P/E | — | 20.45 |
| EPS (TTM) | $-2.36 | $2.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $829.45M | $616.29M |
| Revenue growth (YoY) | +23258.15% | +87.32% |
| Net income (latest FY) | $-1.63M | $447.18M |
| Gross margin | — | 83.66% |
| Operating margin | 11.86% | 20.01% |
| Net margin | -0.20% | 72.56% |
| 52-week high | $95.49 | $59.30 |
| 52-week low | $34.61 | $26.76 |
| Distance from 52-week high | -34.29% | -6.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +70.88% | +25.90% |
| Average volume | 1.89M | 2.01M |
| Shares outstanding | 141.25M | 153.08M |
| Employees | 711 | 399 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARWR has outperformed TGTX by 15.2 percentage points over the past year.
- TG Therapeutics is more profitable, keeping 72.6 cents of every revenue dollar as net income versus -0.2 cents for Arrowhead Pharmaceuticals.
- Arrowhead Pharmaceuticals grew revenue faster in its latest fiscal year (+23258.15% vs +87.32%).
About Arrowhead Pharmaceuticals
ARWR stock →Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 711 employees
About TG Therapeutics
TGTX stock →TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 399 employees
ARWR vs TGTX FAQ
Which is bigger, Arrowhead Pharmaceuticals or TG Therapeutics?
Arrowhead Pharmaceuticals (ARWR) is larger, with a market capitalization of $8.86B compared with $8.48B for TG Therapeutics (TGTX).
Which stock has performed better over the past year, ARWR or TGTX?
ARWR returned +64.43% over the past 12 months, compared with +49.20% for TGTX (price return, excluding dividends). Past performance does not predict future results.
Are Arrowhead Pharmaceuticals and TG Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.